Colchicine for alcoholic and non-alcoholic liver fibrosis and cirrhosis

Abstract

Cochrane Database of Systematic Reviews Colchicine for alcoholic and non-alcoholic liver fibrosis and cirrhosis (Review)Rambaldi A, Gluud C Rambaldi A, Gluud C. Colchicine for alcoholic and non-alcoholic liver fibrosis and cirrhosis.

The Combination of Schisandrol B and Wedelolactone Synergistically Reverses Hepatic Fibrosis Via Modulating Multiple Signaling Pathways in Mice

“…Considering the obviously hepato-protective effect, we tested the role of SolB in mouse model of hepatic fibrosis induced by bile duct ligation (BDL) ligation. The livers of mice treated with colchicine (colchicine has been used for the treatment of liver fibrosis ( Rambaldi and Gluud, 2005 ) and was used as a positive control in this study, 0.2 mg/kg per day) or SolB (10, 20, and 40 mg/kg per day, respectively) exhibited a remarkably lower cirrhotic appearance with varying degrees ( Figures 2A–D ). Furthermore, the histological assessment of liver sections by H&E staining, Sirius red, and Masson staining demonstrated that treatment with SolB inhibited hepatic injury and fibrosis in mice induced by BDL ( Figures 2A,B ).…”

The Combination of Schisandrol B and Wedelolactone Synergistically Reverses Hepatic Fibrosis Via Modulating Multiple Signaling Pathways in Mice

“…Considering the obviously hepato-protective effect, we tested the role of SolB in mouse model of hepatic fibrosis induced by bile duct ligation (BDL) ligation. The livers of mice treated with colchicine (colchicine has been used for the treatment of liver fibrosis ( Rambaldi and Gluud, 2005 ) and was used as a positive control in this study, 0.2 mg/kg per day) or SolB (10, 20, and 40 mg/kg per day, respectively) exhibited a remarkably lower cirrhotic appearance with varying degrees ( Figures 2A–D ). Furthermore, the histological assessment of liver sections by H&E staining, Sirius red, and Masson staining demonstrated that treatment with SolB inhibited hepatic injury and fibrosis in mice induced by BDL ( Figures 2A,B ).…”

Colchicine—Update on mechanisms of action and therapeutic uses

“…In a placebo-controlled multicenter study in 549 patients with advanced alcoholic cirrhosis [95], colchicine failed to reproduce the previously reported favorable effect on mortality [96]. A meta-analysis combining the results of 15 RCTs encompassing 1,714 subjects with alcoholic or non-alcoholic liver cirrhosis, demonstrated no significant effects of colchicine on mortality, liver related mortality, complications and other outcomes [97]. In a recent double blind, randomized controlled trial in 74 subjects with chronic liver cirrhosis and who could not be treated with alpha-interferon, Muntoni et al demonstrated that colchicine 1mg daily significantly increased survival (94.6% vs 78.4% p=0.001), and decreased serum N-terminal peptide of type III procollagen (a biomarker of liver fibrosis) over a follow up period of 4.4 years [98].…”

Pathophysiology and Management of Alcoholic Liver Disease: Update 2016

“…The same fate is shared by data on propylthiouracil,122 col-chicine,123 S-Adenosyl-L-methionine (SAMe),124 and polyenyl-phosphatidylcholine125 which all proved no more effective than placebo in the treatment of ALD.…”

The Combination of Schisandrol B and Wedelolactone Synergistically Reverses Hepatic Fibrosis Via Modulating Multiple Signaling Pathways in Mice

“…Considering the obviously hepato-protective effect, we tested the role of SolB in mouse model of hepatic fibrosis induced by bile duct ligation (BDL) ligation. The livers of mice treated with colchicine (colchicine has been used for the treatment of liver fibrosis ( Rambaldi and Gluud, 2005 ) and was used as a positive control in this study, 0.2 mg/kg per day) or SolB (10, 20, and 40 mg/kg per day, respectively) exhibited a remarkably lower cirrhotic appearance with varying degrees ( Figures 2A–D ). Furthermore, the histological assessment of liver sections by H&E staining, Sirius red, and Masson staining demonstrated that treatment with SolB inhibited hepatic injury and fibrosis in mice induced by BDL ( Figures 2A,B ).…”

Colchicine—Update on mechanisms of action and therapeutic uses

“…In a placebo-controlled multicenter study in 549 patients with advanced alcoholic cirrhosis [95], colchicine failed to reproduce the previously reported favorable effect on mortality [96]. A meta-analysis combining the results of 15 RCTs encompassing 1,714 subjects with alcoholic or non-alcoholic liver cirrhosis, demonstrated no significant effects of colchicine on mortality, liver related mortality, complications and other outcomes [97]. In a recent double blind, randomized controlled trial in 74 subjects with chronic liver cirrhosis and who could not be treated with alpha-interferon, Muntoni et al demonstrated that colchicine 1mg daily significantly increased survival (94.6% vs 78.4% p=0.001), and decreased serum N-terminal peptide of type III procollagen (a biomarker of liver fibrosis) over a follow up period of 4.4 years [98].…”

Pathophysiology and Management of Alcoholic Liver Disease: Update 2016

“…The same fate is shared by data on propylthiouracil,122 col-chicine,123 S-Adenosyl-L-methionine (SAMe),124 and polyenyl-phosphatidylcholine125 which all proved no more effective than placebo in the treatment of ALD.…”

The Combination of Schisandrol B and Wedelolactone Synergistically Reverses Hepatic Fibrosis Via Modulating Multiple Signaling Pathways in Mice

“…Considering the obviously hepato-protective effect, we tested the role of SolB in mouse model of hepatic fibrosis induced by bile duct ligation (BDL) ligation. The livers of mice treated with colchicine (colchicine has been used for the treatment of liver fibrosis ( Rambaldi and Gluud, 2005 ) and was used as a positive control in this study, 0.2 mg/kg per day) or SolB (10, 20, and 40 mg/kg per day, respectively) exhibited a remarkably lower cirrhotic appearance with varying degrees ( Figures 2A–D ). Furthermore, the histological assessment of liver sections by H&E staining, Sirius red, and Masson staining demonstrated that treatment with SolB inhibited hepatic injury and fibrosis in mice induced by BDL ( Figures 2A,B ).…”

Colchicine—Update on mechanisms of action and therapeutic uses

“…In a placebo-controlled multicenter study in 549 patients with advanced alcoholic cirrhosis [95], colchicine failed to reproduce the previously reported favorable effect on mortality [96]. A meta-analysis combining the results of 15 RCTs encompassing 1,714 subjects with alcoholic or non-alcoholic liver cirrhosis, demonstrated no significant effects of colchicine on mortality, liver related mortality, complications and other outcomes [97]. In a recent double blind, randomized controlled trial in 74 subjects with chronic liver cirrhosis and who could not be treated with alpha-interferon, Muntoni et al demonstrated that colchicine 1mg daily significantly increased survival (94.6% vs 78.4% p=0.001), and decreased serum N-terminal peptide of type III procollagen (a biomarker of liver fibrosis) over a follow up period of 4.4 years [98].…”

Pathophysiology and Management of Alcoholic Liver Disease: Update 2016

“…The same fate is shared by data on propylthiouracil,122 col-chicine,123 S-Adenosyl-L-methionine (SAMe),124 and polyenyl-phosphatidylcholine125 which all proved no more effective than placebo in the treatment of ALD.…”